CSF Pharmacokinetics of Ondansetron

• Status: Completed
• Trial end date: 2016-11-17
• Target enrollment: 0
• Participant gender: All

Summary

Serotonergic 5-HT3 receptors in the central nervous system are involved in pain processing after nerve injury. We are interested in learning if 5-HT3 receptor antagonist ondansetron might be an appropriate drug for treating pain after nerve injury (neuropathic pain), by investigating its bio-distribution in the cerebro-spinal fluid, and the genetic variability that may affect that distribution.

Study procedures will include iv ondansetron administration, serial blood draws, cerebrospinal fluid (CSF) sampling, pregnancy testing, and possible ECG.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Ondansetron

Criteria

Inclusion Criteria:

1. Age between 18 and 70 years old;

2. Patients planned to undergo hip or knee arthroplasty with spinal anesthesia;

3. Ability to provide informed consent

Exclusion Criteria:

1. Not giving consent to participate in the study;

2. Patients with history of or current hepatic or renal insufficiency;

3. Patients with BMI ≥ 33;

4. Patients with heart failure or active arrhythmias;

5. Patients with severe systemic disease that is a constant threat to life;

6. Contraindication or allergy to ondansetron;

7. Pregnancy or lactation.

8. Prisoners